FR3017298B1 - Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires - Google Patents

Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Info

Publication number
FR3017298B1
FR3017298B1 FR1450956A FR1450956A FR3017298B1 FR 3017298 B1 FR3017298 B1 FR 3017298B1 FR 1450956 A FR1450956 A FR 1450956A FR 1450956 A FR1450956 A FR 1450956A FR 3017298 B1 FR3017298 B1 FR 3017298B1
Authority
FR
France
Prior art keywords
conjugates
pro
drugs
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1450956A
Other languages
English (en)
French (fr)
Other versions
FR3017298A1 (fr
Inventor
Sebastien Papot
Isabelle Opalinski
Brigitte Renoux
Thibaut Legigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1450956A priority Critical patent/FR3017298B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CN201580018638.0A priority patent/CN106573071A/zh
Priority to PCT/IB2015/050914 priority patent/WO2015118497A1/fr
Priority to JP2016550736A priority patent/JP6721512B2/ja
Priority to CN202210334259.4A priority patent/CN114917358A/zh
Priority to US15/117,069 priority patent/US10293021B2/en
Priority to ES15709742T priority patent/ES2843798T3/es
Priority to CA2938501A priority patent/CA2938501C/fr
Priority to EP15709742.9A priority patent/EP3139963B1/fr
Priority to DK15709742.9T priority patent/DK3139963T3/da
Priority to EP20192895.9A priority patent/EP3766510A1/fr
Publication of FR3017298A1 publication Critical patent/FR3017298A1/fr
Application granted granted Critical
Publication of FR3017298B1 publication Critical patent/FR3017298B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR1450956A 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires Expired - Fee Related FR3017298B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
EP15709742.9A EP3139963B1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires
JP2016550736A JP6721512B2 (ja) 2014-02-07 2015-02-06 がん及び炎症性疾患の治療のための結合体及びプロドラッグ
CN202210334259.4A CN114917358A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药
US15/117,069 US10293021B2 (en) 2014-02-07 2015-02-06 Conjugates and prodrugs for treating cancer and inflammatory diseases
ES15709742T ES2843798T3 (es) 2014-02-07 2015-02-06 Conjugados y profármacos para el tratamiento del cáncer y de enfermedades inflamatorias
CN201580018638.0A CN106573071A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药
PCT/IB2015/050914 WO2015118497A1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires
DK15709742.9T DK3139963T3 (da) 2014-02-07 2015-02-06 Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme
EP20192895.9A EP3766510A1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires
CA2938501A CA2938501C (fr) 2014-02-07 2015-02-06 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Publications (2)

Publication Number Publication Date
FR3017298A1 FR3017298A1 (fr) 2015-08-14
FR3017298B1 true FR3017298B1 (fr) 2016-03-04

Family

ID=50829100

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1450956A Expired - Fee Related FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Country Status (9)

Country Link
US (1) US10293021B2 (enExample)
EP (2) EP3139963B1 (enExample)
JP (1) JP6721512B2 (enExample)
CN (2) CN106573071A (enExample)
CA (1) CA2938501C (enExample)
DK (1) DK3139963T3 (enExample)
ES (1) ES2843798T3 (enExample)
FR (1) FR3017298B1 (enExample)
WO (1) WO2015118497A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722593B2 (en) 2015-10-02 2020-07-28 Sirenas Llc Anti-cancer compounds and conjugates thereof
CN108779146B (zh) * 2016-03-29 2022-03-18 东丽株式会社 肽衍生物及其用途
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
AU2018375787B2 (en) * 2017-11-30 2023-02-23 Ladrx Corporation Albumin-binding prodrugs of auristatin E derivatives
CN120078904A (zh) * 2018-04-03 2025-06-03 辛迪维亚公司 细胞毒性药物的结合物和所述结合物的前体药物形式
JP7620569B2 (ja) * 2019-05-06 2025-01-23 セーキョー がん治療のための新規治療用ベクター及びプロドラッグ
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN116077674B (zh) * 2022-12-26 2025-03-25 北京大学 生物分子-聚氮氧化物偶联物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PT3248613T (pt) * 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
FR2960153B1 (fr) * 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant

Also Published As

Publication number Publication date
ES2843798T3 (es) 2021-07-20
CN106573071A (zh) 2017-04-19
CN114917358A (zh) 2022-08-19
EP3766510A1 (fr) 2021-01-20
US10293021B2 (en) 2019-05-21
CA2938501A1 (fr) 2015-08-13
FR3017298A1 (fr) 2015-08-14
JP2017506628A (ja) 2017-03-09
DK3139963T3 (da) 2020-10-26
EP3139963B1 (fr) 2020-10-07
JP6721512B2 (ja) 2020-07-15
CA2938501C (fr) 2022-04-05
US20170095525A1 (en) 2017-04-06
WO2015118497A1 (fr) 2015-08-13
EP3139963A1 (fr) 2017-03-15

Similar Documents

Publication Publication Date Title
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3661955A4 (en) CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3448875A4 (en) Compositions for the treatment of disease
EP3488001A4 (en) TREATMENT OF CANCER
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
IL323562A (en) Methods for treating inflammatory diseases
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
EP3370703A4 (en) GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
PL3169328T3 (pl) Pochodne chinoliny do leczenia chorób zapalnych
EP3285773A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
EP2983791A4 (en) METHOD AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES
EP3389645A4 (en) COMBINATIONS FOR TREATING CANCER
FR3017298B1 (fr) Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
EP3359192A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
IL257561A (en) Methods for treating inflammatory diseases
MA47408A (fr) Traitement du cancer
EP3383407A4 (en) CYTARABIN CONJUGATES FOR CANCER THERAPY
EP3383497A4 (en) NOVEL ANTIBODIES FOR THE TREATMENT OF CANCER DISEASES
EP2967062A4 (en) DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION
MA46361A (fr) Traitement du cancer de la prostate
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20221005